<< Back to News

System Formulary Update
Cabotegravir (Apretude)

Situation

Cabotegravir (Apretude) 600 mg/3 mL extended-release injection was approved for addition to the health system formulary at the March 2023 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed:

• Cabotegravir (Apretude) 600 mg/3 mL extended-release injection

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary with restriction to outpatient/clinic use only (ie, no inpatient use):

• Cabotegravir (Apretude) 600 mg/3 mL extended-release injection

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, April 25, 2023.